Figure 2.
IC50 values of DOX⋅HCl against (A) MCF-7/ADR cells and (B) K562/ADR cells in the form of free drug mixtures with CQ at different mass ratios; (C) Reversal index of DOX⋅HCl and (D) combination index of DOX⋅HCl and CQ at different mass ratios on MCF-7/ADR and K562/ADR cells (CI<0.1, very strong synergism; CI = 0.1-0.3, strong synergism; CI = 0.3-0.7, synergism; CI = 0.7-0.85, moderate synergism; CI = 0.85-0.90, slight synergism; CI = 0.90-1.10, nearly additive; CI =1, additive; CI>1, antagonistic.); IC50 values of DOX⋅HCl and reversal index after treated with D-DIV/C or DC-DIV/C against (E) MCF-7/ADR cells and (F) K562/ADR cells; Apoptosis of (G) MCF-7/ADR cells and (H) K562/ADR cells after treatment with different formulations for 48 h.